FDA Grants Orphan Drug Designation to AAVantgarde Bio’s AAVB-081 for Usher Syndrome Type 1B Treatment
FDA Grants Orphan Drug Designation to AAVantgarde Bio's AAVB-081 for Usher Syndrome Type 1B Treatment AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company ...
Nanoscope Therapeutics Prepares BLA Submission for MCO-010 in Retinitis Pigmentosa Following FDA Meeting
Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company dedicated to developing gene therapies for retinal degenerative diseases, has announced a successful FDA meeting for its clinic ...